Clinical Oncology Next Generation Sequencing Market - Global Industry Analysis

The report covers forecast and analysis for the Clinical Oncology Next Generation Sequencing market on a global and regional level. The study provides historic data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the Clinical Oncology Next Generation Sequencing market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Clinical Oncology Next Generation Sequencing market on a global level. In order to give the users of this report a comprehensive view on the Clinical Oncology Next Generation Sequencing market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein technology, workflow, application, end user and regional segments are benchmarked based on their market size, growth rate and general attractiveness.

As genomics-focused pharmacology is beginning to play a greater role in the treatment of cancer, next-generation sequencing (NGS) is emerging as a valuable method for obtaining a deeper and more accurate look into individual tumor molecular background. With tailored therapies becoming the latest oncology standard of care, NGS-driven companion diagnostics are widely viewed as improving treatment choice to improve future patient outcomes.

The study provides a decisive view on the Clinical Oncology Next Generation Sequencing market by segmenting the market based on technology, workflow, application, end user and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. Based on technology, the market is segmented into Whole genome sequencing, whole exome sequencing and targeted sequencing & re-sequencing. Targeted clinical oncology sequencing represented the largest share of revenue in 2018 and is expected to maintain its share over the forecast period. Targeted sequencing and resequencing is one of the conventional forms of commercially available sequencing technology and includes the shortest reading lengths. Based on workflow, the market is segmented into NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis. Sequencing was the largest share in the NGS market for clinical oncology as it is the most important and crucial step in the entire process and involves the use of sophisticated platforms. Continuous R&D has culminated in the introduction of new, benchtop and portable NGS sequencing platforms, complimenting the growth of the industry. Based on application, the market is segmented into screening, companion diagnostics and others. Adoption of NGS-based oncology molecular diagnosis has increased as this technology allows multiple target genes to be sequenced simultaneously and provides rich diagnostic markers for molecular diagnostic assays to be produced. Based on end-user, the market is segmented into Hospitals, Clinics, Laboratories and others. Laboratories held a prominent market share for NGS clinical oncology and this trend is expected to continue over the forecast period. The segment of hospitals is expected to record a significant CAGR by 2025. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa with its further bifurcation into major countries such as US, Canada, Germany, UK, France, China, Japan, India, GCC countries, Brazil. In 2018, North America occupied the largest share of the global market due to increased government focus on cancer treatment, increased healthcare expenditure, and adequate healthcare infrastructure. In addition, high cancer prevalence, increased demand for personalized medicine, well-developed healthcare facilities, and the availability of new diagnostic techniques, particularly in the area of oncology, can be attributed to the region's estimated market share.

Over the past few years, breakthrough developments in the production of genetic-based oncology testing and other diseases have accelerated market growth dramatically. Sequencing technology of the next decade offers a better understanding of the tumor function, thereby allowing a rational development of medicines. As a consequence, in the near future, more goods are likely to be sold. It is further predicted that an increase in oncology-related spending would fuel market growth in the coming years. Government organizations are focused on encouraging patients to undergo diagnostic examinations on a regular basis to reduce healthcare expenses related to oncology. Healthcare spending is expected to increase significantly, according to data projections, thus affecting the adoption of the NGS diagnostics platform.

Key players within global Clinical Oncology Next Generation Sequencing market include Agilent, Beijing Genomics Institute (BGI), Caris Life Sciences, Eurofins Scientific, Foundation Medicine, Myriad Genetics, Oxford Nanopore Technologies Ltd., Pacific Bioscience, Inc., Paradigm Diagnostics, Inc., Partek, Inc., Perkin Elmer, Inc., Qiagen NV, Thermo Fisher Scientific amongst others.

The report segments global Clinical Oncology Next Generation Sequencing market as follows:

Global Clinical Oncology Next Generation Sequencings Market: Technology Segment Analysis

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing

Global Clinical Oncology Next Generation Sequencings Market: Workflow Segment Analysis

• NGS Pre-Sequencing
• NGS Sequencing
• NGS Data Analysis

Global Clinical Oncology Next Generation Sequencings Market: Application Segment Analysis

• Screening
  • Sporadic Cancer
  • Inherited Cancer
• Companion Diagnostics
• Others

Global Clinical Oncology Next Generation Sequencings Market: End User Segment Analysis

• Hospitals
• Clinics
• Laboratories
• Others

Global Clinical Oncology Next Generation Sequencing Market: Regional Segment Analysis

• North America
  • U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa

• Chapter 1. Preface
  • 1.1. Report Description and Scope
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology
• Chapter 2. Executive Summary
  • 2.1. Clinical Oncology Next Generation Sequencings Market, 2016-2025 (USD Million)
  • 2.2. Clinical Oncology Next Generation Sequencings Market: Snapshot
• Chapter 3. Clinical Oncology Next Generation Sequencings Market - Industry Analysis
  • 3.1. Clinical Oncology Next Generation Sequencings Market: Market Dynamics
  • 3.2. Market Drivers
    • 3.2.1. Driver 1
    • 3.2.2. Driver 2
  • 3.3. Restraints
    • 3.3.1. Restraint 1
    • 3.3.2. Restraint 2
  • 3.4. Opportunity
    • 3.4.1. Government funding and support
  • 3.5. Porter's Five Forces Analysis
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. Market attractiveness analysis By Technology
    • 3.6.2. Market attractiveness analysis By Workflow
    • 3.6.3. Market attractiveness analysis By Application
    • 3.6.4. Market attractiveness analysis By End User
    • 3.6.5. Market attractiveness analysis by Region
• Chapter 4. Clinical Oncology Next Generation Sequencings Market- Competitive Landscape
  • 4.1. Company market share analysis
    • 4.1.1. Global Clinical Oncology Next Generation Sequencings Market: company market share, 2018
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New Technology launches
    • 4.2.3. Agreements, partnerships, collaborations and joint ventures
    • 4.2.4. Research and development and Regional expansion
  • 4.3. Price trend analysis
• Chapter 5. Global Clinical Oncology Next Generation Sequencings Market -Technology Analysis
  • 5.1. Global Clinical Oncology Next Generation Sequencings Market overview: By Technology type
    • 5.1.1. Global Clinical Oncology Next Generation Sequencings Market share, By Technology,2018 and 2025
  • 5.2. Whole Genome Sequencing
    • 5.2.1. Global Clinical Oncology Next Generation Sequencings Market by Whole Genome Sequencing, 2016-2025 (USD Million)
  • 5.3. Whole Exome Sequencing
    • 5.3.1. Global Clinical Oncology Next Generation Sequencings Market by Whole Exome Sequencing, 2016-2025 (USD Million)
  • 5.4. Targeted Sequencing & Resequencing
    • 5.4.1. Global Clinical Oncology Next Generation Sequencings Market by Targeted Sequencing & Resequencing, 2016-2025 (USD Million)
• Chapter 6. Global Clinical Oncology Next Generation Sequencings Market -Workflow Analysis
  • 6.1. Global Clinical Oncology Next Generation Sequencings Market overview: By Workflow
    • 6.1.1. Global Clinical Oncology Next Generation Sequencings Market share, By Workflow, 2018 and 2025
  • 6.2. NGS Pre-Sequencing
    • 6.2.1. Global Clinical Oncology Next Generation Sequencings Market By NGS Pre-Sequencing, 2016-2025 (USD Million)
  • 6.3. NGS Sequencing
    • 6.3.1. Global Clinical Oncology Next Generation Sequencings Market By NGS Sequencing, 2016-2025 (USD Million)
  • 6.4. NGS Data Analysis
    • 6.4.1. Global Clinical Oncology Next Generation Sequencings Market By NGS Data Analysis, 2016-2025 (USD Million)
• Chapter 7. Global Clinical Oncology Next Generation Sequencings Market -Application Analysis
  • 7.1. Global Clinical Oncology Next Generation Sequencings Market overview: By Application
    • 7.1.1. Global Clinical Oncology Next Generation Sequencings Market share, By Application, 2018 and 2025
  • 7.2. Screening
    • 7.2.1. Global Clinical Oncology Next Generation Sequencings Market by Screening, 2016-2025 (USD Million)
  • 7.3. Sporadic Cancer
    • 7.3.1. Global Clinical Oncology Next Generation Sequencings Market by Sporadic Cancer, 2016-2025 (USD Million)
  • 7.4. Inherited Cancer
    • 7.4.1. Global Clinical Oncology Next Generation Sequencings Market by Inherited Cancer, 2016-2025 (USD Million)
  • 7.5. Companion Diagnostics
    • 7.5.1. Global Clinical Oncology Next Generation Sequencings Market by others, 2016-2025 (USD Million)
  • 7.6. Others
    • 7.6.1. Global Clinical Oncology Next Generation Sequencings Market by Application others, 2016-2025 (USD Million)
• Chapter 8. Global Clinical Oncology Next Generation Sequencings Market - End User Analysis
  • 8.1. Global Clinical Oncology Next Generation Sequencings Market overview: By End User
    • 8.1.1. Global Clinical Oncology Next Generation Sequencings Market share, By End User, 2018 and 2025
  • 8.2. Hospitals
    • 8.2.1. Global Clinical Oncology Next Generation Sequencings Market by Hospitals, 2016-2025 (USD Million)
  • 8.3. Clinics
    • 8.3.1. Global Clinical Oncology Next Generation Sequencings Market by Clinics, 2016-2025 (USD Million)
  • 8.4. Laboratories
    • 8.4.1. Global Clinical Oncology Next Generation Sequencings Market by Laboratories, 2016-2025 (USD Million)
  • 8.5. Others
    • 8.5.1. Global Clinical Oncology Next Generation Sequencings Market by End User Others, 2016-2025 (USD Million)
• Chapter 9. Global Clinical Oncology Next Generation Sequencings Market - Regional Analysis
  • 9.1. Global Clinical Oncology Next Generation Sequencings Market overview: by Region
    • 9.1.1. Global Clinical Oncology Next Generation Sequencings Marketshare, by Region, 2018 and 2025
  • 9.2. North America
    • 9.2.1. North America Clinical Oncology Next Generation Sequencings Market, 2016-2025 (USD Million)
    • 9.2.2. North America Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
    • 9.2.3. North America Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
    • 9.2.4. North America Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
    • 9.2.5. North America Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
    • 9.2.6. The U.S.
      • 9.2.6.1. The U.S.Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
      • 9.2.6.2. The U.S.Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
      • 9.2.6.3. The U.S.Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
      • 9.2.6.4. The U.S.Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
    • 9.2.7. Rest of North America
      • 9.2.7.1. Rest of North America Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
      • 9.2.7.2. Rest of North America Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
      • 9.2.7.3. Rest of North America Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
      • 9.2.7.4. Rest of North America Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
  • 9.3. Europe
    • 9.3.1. Europe Clinical Oncology Next Generation Sequencings Market, 2016-2025 (USD Million)
    • 9.3.2. Europe Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
    • 9.3.3. Europe Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
    • 9.3.4. Europe Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
    • 9.3.5. Europe Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
    • 9.3.6. UK
      • 9.3.6.1. U.K.Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
      • 9.3.6.2. U.K.Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
      • 9.3.6.3. U.K. Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
      • 9.3.6.4. U.K. Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
    • 9.3.7. France
      • 9.3.7.1. France Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
      • 9.3.7.2. France Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
      • 9.3.7.3. France Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
      • 9.3.7.4. France Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
    • 9.3.8. Germany
      • 9.3.8.1. Germany Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
      • 9.3.8.2. Germany Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
      • 9.3.8.3. Germany Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
      • 9.3.8.4. Germany Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
    • 9.3.9. Rest of Europe
      • 9.3.9.1. Rest of EuropeClinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
      • 9.3.9.2. Rest of EuropeClinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
      • 9.3.9.3. Rest of Europe Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
      • 9.3.9.4. Rest of Europe Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific Clinical Oncology Next Generation Sequencings Market, 2016-2025 (USD Million)
    • 9.4.2. Asia Pacific Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
    • 9.4.3. Asia Pacific Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
    • 9.4.4. Asia Pacific Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
    • 9.4.5. Asia Pacific Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
    • 9.4.6. China
      • 9.4.6.1. China Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
      • 9.4.6.2. China Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
      • 9.4.6.3. China Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
      • 9.4.6.4. China Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million
    • 9.4.7. Japan
      • 9.4.7.1. Japan Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
      • 9.4.7.2. Japan Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
      • 9.4.7.3. Japan Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
      • 9.4.7.4. Japan Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
    • 9.4.8. India
      • 9.4.8.1. India Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
      • 9.4.8.2. India Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
      • 9.4.8.3. India Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
      • 9.4.8.4. India Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
    • 9.4.9. Rest of Asia Pacific
      • 9.4.9.1. Rest of Asia Pacific Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
      • 9.4.9.2. Rest of Asia Pacific Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
      • 9.4.9.3. Rest of Asia Pacific Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
      • 9.4.9.4. Rest of Asia Pacific Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
  • 9.5. Latin America
    • 9.5.1. Latin America Clinical Oncology Next Generation Sequencings Market, 2016-2025 (USD Million)
    • 9.5.2. Latin America Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
    • 9.5.3. Latin America Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
    • 9.5.4. Latin America Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
    • 9.5.5. Latin America Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Brazil Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
      • 9.5.6.2. Brazil Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
      • 9.5.6.3. Brazil Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
      • 9.5.6.4. Brazil Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
    • 9.5.7. Rest of LatinAmerica
      • 9.5.7.1. Rest of LatinAmerica Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
      • 9.5.7.2. Rest of LatinAmerica Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
      • 9.5.7.3. Rest of Latin America Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
      • 9.5.7.4. Rest of Latin America Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
  • 9.6. The Middle East and Africa
    • 9.6.1. The Middle East and Africa Clinical Oncology Next Generation Sequencings Market, 2016-2025 (USD Million)
    • 9.6.2. The Middle East and Africa Clinical Oncology Next Generation Sequencings Market revenue, By Technology,2016-2025 (USD Million)
    • 9.6.3. The Middle East and Africa Clinical Oncology Next Generation Sequencings Market revenue, By Workflow, 2016-2025 (USD Million)
    • 9.6.4. The Middle East and Africa Clinical Oncology Next Generation Sequencings Market revenue, By Application, 2016-2025 (USD Million)
    • 9.6.5. The Middle East and Africa Clinical Oncology Next Generation Sequencings Market revenue, By End User, 2016-2025 (USD Million)
• Chapter 10. Company Profiles
  • 10.1. Agilent
    • 10.1.1. Overview
    • 10.1.2. Financials
    • 10.1.3. Technology Portfolio
    • 10.1.4. Business Strategy
    • 10.1.5. Recent Developments
  • 10.2. Beijing Genomics Institute (BGI)
    • 10.2.1. Overview
    • 10.2.2. Financials
    • 10.2.3. Technology Portfolio
    • 10.2.4. Business Strategy
    • 10.2.5. Recent Developments
  • 10.3. Caris Life Sciences
    • 10.3.1. Overview
    • 10.3.2. Financials
    • 10.3.3. Technology Portfolio
    • 10.3.4. Business Strategy
    • 10.3.5. Recent Developments
  • 10.4. Eurofins Scientific
    • 10.4.1. Overview
    • 10.4.2. Financials
    • 10.4.3. Technology Portfolio
    • 10.4.4. Business Strategy
    • 10.4.5. Recent Developments
  • 10.5. Foundation Medicine
    • 10.5.1. Overview
    • 10.5.2. Financials
    • 10.5.3. Technology Portfolio
    • 10.5.4. Business Strategy
    • 10.5.5. Recent Development
  • 10.6. Myriad Genetics
    • 10.6.1. Overview
    • 10.6.2. Financials
    • 10.6.3. Technology Portfolio
    • 10.6.4. Business Strategy
    • 10.6.5. Recent Development
  • 10.7. Oxford Nanopore Technologies Ltd.
    • 10.7.1. Overview
    • 10.7.2. Financials
    • 10.7.3. Technology Portfolio
    • 10.7.4. Business Strategy
    • 10.7.5. Recent Development
  • 10.8. Pacific Bioscience, Inc.
    • 10.8.1. Overview
    • 10.8.2. Financials
    • 10.8.3. Technology Portfolio
    • 10.8.4. Business Strategy
    • 10.8.5. Recent Development
  • 10.9. Paradigm Diagnostics, Inc.
    • 10.9.1. Overview
    • 10.9.2. Financials
    • 10.9.3. Technology Portfolio
    • 10.9.4. Business Strategy
    • 10.9.5. Recent Development
  • 10.10. Partek, Inc.
    • 10.10.1. Overview
    • 10.10.2. Financials
    • 10.10.3. Technology Portfolio
    • 10.10.4. Business Strategy
    • 10.10.5. Recent Development